PT2397142T - Utilizações de inibidores da dpp iv - Google Patents

Utilizações de inibidores da dpp iv

Info

Publication number
PT2397142T
PT2397142T PT111799086T PT11179908T PT2397142T PT 2397142 T PT2397142 T PT 2397142T PT 111799086 T PT111799086 T PT 111799086T PT 11179908 T PT11179908 T PT 11179908T PT 2397142 T PT2397142 T PT 2397142T
Authority
PT
Portugal
Prior art keywords
dpp
inhibitors
Prior art date
Application number
PT111799086T
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38235138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2397142(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PT2397142T publication Critical patent/PT2397142T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Inorganic Chemistry (AREA)
PT111799086T 2006-05-04 2007-05-03 Utilizações de inibidores da dpp iv PT2397142T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06009203 2006-05-04

Publications (1)

Publication Number Publication Date
PT2397142T true PT2397142T (pt) 2022-08-22

Family

ID=38235138

Family Applications (2)

Application Number Title Priority Date Filing Date
PT77287233T PT2015754E (pt) 2006-05-04 2007-05-03 Utilizações de inibidores da dpp iv
PT111799086T PT2397142T (pt) 2006-05-04 2007-05-03 Utilizações de inibidores da dpp iv

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT77287233T PT2015754E (pt) 2006-05-04 2007-05-03 Utilizações de inibidores da dpp iv

Country Status (35)

Country Link
US (8) US8232281B2 (pt)
EP (5) EP2351568A3 (pt)
JP (12) JP5734564B2 (pt)
KR (9) KR101558938B1 (pt)
CN (8) CN110227078A (pt)
AR (1) AR060757A1 (pt)
AU (1) AU2007247141B2 (pt)
BR (1) BRPI0711308A2 (pt)
CA (4) CA2875706C (pt)
CL (3) CL2012002526A1 (pt)
CY (1) CY1115350T1 (pt)
DK (1) DK2015754T3 (pt)
EA (3) EA202091999A3 (pt)
EC (1) ECSP088866A (pt)
ES (2) ES2474866T3 (pt)
HK (1) HK1204548A1 (pt)
HR (1) HRP20140645T1 (pt)
IL (1) IL195031A0 (pt)
ME (1) ME01787B (pt)
MX (3) MX2008014025A (pt)
MY (3) MY172012A (pt)
NO (1) NO345061B1 (pt)
NZ (2) NZ609765A (pt)
PE (2) PE20080251A1 (pt)
PH (2) PH12013501790B1 (pt)
PL (1) PL2015754T3 (pt)
PT (2) PT2015754E (pt)
RS (1) RS53272B (pt)
SG (1) SG171648A1 (pt)
SI (1) SI2015754T1 (pt)
TW (2) TWI500423B (pt)
UA (1) UA102669C2 (pt)
UY (1) UY30321A1 (pt)
WO (1) WO2007128761A2 (pt)
ZA (1) ZA200808282B (pt)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2444772T3 (es) * 2001-02-24 2014-02-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Derivados de xantina, su preparación y uso como medicamentos
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) * 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7482337B2 (en) * 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) * 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7566707B2 (en) * 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10355304A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de) * 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7179809B2 (en) * 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7439370B2 (en) * 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004030502A1 (de) * 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004043944A1 (de) * 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) * 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
AU2006289093A1 (en) * 2005-09-08 2007-03-15 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
UY30082A1 (es) 2006-01-11 2007-08-31 Boehringer Ingelheim Int Forma cristalina de 1-(1-metiletil)-4`-((2-fluoro-4-metoxifenil)metil)-5`- metil-1h-pirazol-3`-o-b-d-glucopiranosido, un metodo para su preparacion y el uso de la misma para preparar medicamentos
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
CA2810522A1 (en) * 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Polymorphs
US20080020987A1 (en) * 2006-07-20 2008-01-24 Waldemar Pfrengle Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes
JP2010500326A (ja) 2006-08-08 2010-01-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病の治療のためのｄｐｐ−ｉｖ阻害剤としてのピロロ［３，２−ｄ］ピリミジン
WO2008020011A1 (en) * 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
EP2086991A1 (en) * 2006-10-27 2009-08-12 Boehringer Ingelheim International GmbH CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
CL2008002424A1 (es) * 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido; y uso de la composicion farmaceutica para el tratamiento de la diabetes mellitus, tolerancia anormal a la glucosa e hiperglucemia, trastornos metabolicos, entre otras.
PE20090603A1 (es) * 2007-08-16 2009-06-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv
PE20090597A1 (es) * 2007-08-16 2009-06-06 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido
CL2008002427A1 (es) * 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
NZ600126A (en) 2007-08-17 2013-12-20 Boehringer Ingelheim Int Purine derivatives for use in the treatment of fap-related diseases
WO2009068617A1 (en) * 2007-11-30 2009-06-04 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-d) pyrimidin-4-one derivatives and their use as pde9a modulators for the teatment of cns disorders
CL2008003653A1 (es) * 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
UA105362C2 (en) * 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
MX2011001525A (es) 2008-08-15 2011-03-29 Boehringer Ingelheim Int Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
US9079905B2 (en) 2008-09-08 2015-07-14 Boehringer Ingelheim International Gmbh Compounds for the treatment of CNS disorders
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CA2744697C (en) 2008-11-26 2016-06-21 Satiogen Pharmaceuticals, Inc. Use of compositions comprising bile acids, salts, and mimics thereof for the treatment of obesity or diabetes
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
TWI466672B (zh) 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
EA029759B1 (ru) * 2009-02-13 2018-05-31 Бёрингер Ингельхайм Интернациональ Гмбх Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
DK2395983T3 (da) 2009-02-13 2020-07-13 Boehringer Ingelheim Int Farmaceutisk sammensætning omfattende en sglt2-inhibitor, en dpp-iv-inhibitor og eventuelt et yderligere antidiabetisk middel og anvendelser deraf
UY32427A (es) * 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
EA024072B1 (ru) * 2009-02-13 2016-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Фармацевтическая дозированная форма, включающая производное глюкопиранозилдифенилметана, и применения для улучшения гликемического контроля у пациентов
EP2414363B1 (en) 2009-03-31 2014-01-08 Boehringer Ingelheim International GmbH 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators
AR077859A1 (es) * 2009-08-12 2011-09-28 Boehringer Ingelheim Int Compuestos para el tratamiento de trastornos del snc
EP2483286B1 (en) 2009-09-30 2016-07-13 Boehringer Ingelheim International GmbH Method for the preparation of a crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
WO2011039108A2 (en) 2009-09-30 2011-04-07 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
UY32919A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
NZ598170A (en) 2009-10-02 2014-06-27 Boehringer Ingelheim Int Pharmaceutical compositions comprising bi-1356 and metformin
ES2760917T3 (es) 2009-11-27 2020-05-18 Boehringer Ingelheim Int Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina
TWI562775B (en) * 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
CN102286011B (zh) * 2010-03-16 2017-10-03 美德（江西）生物科技有限公司 吡咯烷硼酸酯二肽基肽酶抑制剂及其药物组合物
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
JP6034781B2 (ja) 2010-05-05 2016-11-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 併用療法
KR20130069615A (ko) 2010-05-05 2013-06-26 베링거 인겔하임 인터내셔날 게엠베하 피오글리타존 및 리나글립틴을 포함하는 약제학적 제형
CA3164653A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh A combination comprising linagliptin and a long-acting insulin
BR112013003097B1 (pt) 2010-08-12 2021-03-16 Boehringer Ingelheim International Gmbh 6-cicloalquil-pirazolopirimidinonas e composição farmacêutica
US9034883B2 (en) * 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
MX2013007884A (es) 2011-01-07 2013-09-13 Elcelyx Therapeutics Inc Terapias a base de ligando del receptor quimiosensorial.
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
CN102617566B (zh) * 2011-01-30 2015-03-04 山东轩竹医药科技有限公司 吡啶并咪唑烷衍生物
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
EP2680851B1 (en) 2011-03-03 2016-08-17 Merck Sharp & Dohme Corp. Fused bicyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
CN102362866A (zh) * 2011-11-21 2012-02-29 郑飞雄 一种治疗糖尿病及肥胖症的药物组合物
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
EA201491335A1 (ru) 2012-01-06 2015-04-30 Элселикс Терапьютикс, Инк. Бигуанидные композиции и способы лечения метаболических расстройств
CA2860669C (en) * 2012-01-06 2022-05-03 Elcelyx Therapeutics, Inc. Compositions and methods for treating metabolic disorders
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
CN104487070A (zh) * 2012-03-16 2015-04-01 格卢科克斯生物科技有限公司 显示nox4抑制活性的基于噻吩的化合物及其用于治疗的用途
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP2854812A1 (en) 2012-05-24 2015-04-08 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
US20150246117A1 (en) 2012-09-24 2015-09-03 Ulf Eriksson Treatment of type 2 diabetes and related conditions
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SG11201503576XA (en) 2012-12-21 2015-06-29 Sanofi Sa Exendin-4 Derivatives
CA2903577C (en) 2013-03-15 2023-10-17 Boehringer Ingelheim International Gmbh Use of linagliptin in cardio- and renoprotective antidiabetic therapy
CA2897420C (en) 2013-03-27 2020-10-27 F. Hoffmann-La Roche Ag Genetic markers for predicting responsiveness to therapy
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HUE041709T2 (hu) 2013-04-05 2019-05-28 Boehringer Ingelheim Int Az empagliflozin terápiás alkalmazásai
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
AU2014255727B2 (en) 2013-04-18 2019-07-25 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2014184742A1 (en) 2013-05-13 2014-11-20 Ranbaxy Laboratories Limited Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent
CN105283187A (zh) * 2013-06-14 2016-01-27 勃林格殷格翰国际有限公司 用于治疗糖尿病及其并发症的二肽基肽酶-4抑制剂
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
ES2825675T3 (es) 2014-07-30 2021-05-17 Hoffmann La Roche Marcadores genéticos para predecir la reactividad al tratamiento con un agente que aumenta las HDL o que imita las HDL
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
US10813909B2 (en) 2016-05-19 2020-10-27 The Regents Of The University Of California Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ
WO2018104263A1 (en) 2016-12-06 2018-06-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
RU2770775C1 (ru) 2018-05-31 2022-04-21 Хуа Медсин (Шанхай) Лтд. Фармацевтическая комбинация, композиция и комбинированный состав, содержащий активатор глюкокиназы и ингибитор dpp-iv, и способ его приготовления и применения
AU2019306036A1 (en) 2018-07-17 2020-12-17 Boehringer Ingelheim International Gmbh Cardio- and renosafe antidiabetic therapy
WO2020016232A1 (en) 2018-07-17 2020-01-23 Boehringer Ingelheim International Gmbh Cardiosafe antidiabetic therapy
EP3958857A1 (en) * 2019-09-17 2022-03-02 Novartis AG Combination therapy with vildagliptin and metformin
WO2024091863A1 (en) 2022-10-25 2024-05-02 Starrock Pharma Llc Combinatorial, and rotational combinatorial therapies for obesity and other diseases

Family Cites Families (785)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2056046A (en) 1933-05-19 1936-09-29 Rhone Poulenc Sa Manufacture of bases derived from benz-dioxane
US2375138A (en) 1942-05-01 1945-05-01 American Cyanamid Co Alkamine esters of aryloxymethyl benzoic acid
US2629736A (en) 1951-02-24 1953-02-24 Searle & Co Basically substituted n-alkyl derivatives of alpha, beta, beta-triarylpropionamides
US2730544A (en) 1952-07-23 1956-01-10 Sahyun Lab Alkylaminoalkyl esters of hydroxycyclohexylbenzoic acid
US2750387A (en) 1953-11-25 1956-06-12 Searle & Co Basically substituted derivatives of diarylaminobenzamides
DE1211359B (de) 1955-11-29 1966-02-24 Oreal Oxydationsmittelfreies Kaltfaerbemittel fuer menschliches Haar
US2928833A (en) 1959-03-03 1960-03-15 S E Massengill Company Theophylline derivatives
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US3454635A (en) * 1965-07-27 1969-07-08 Hoechst Ag Benzenesulfonyl-ureas and process for their manufacture
DE1914999A1 (de) 1968-04-04 1969-11-06 Ciba Geigy Neue Guanylhydrazone und Verfahren zu ihrer Herstellung
ES385302A1 (es) 1970-10-22 1973-04-16 Miquel S A Lab Procedimiento para la obtencion de derivados trisubstitui- dos de etilendiamina.
DE2205815A1 (de) 1972-02-08 1973-08-16 Hoechst Ag Piperazinderivate und verfahren zu ihrer herstellung
JPS5512435B2 (pt) 1972-07-01 1980-04-02
US4005208A (en) 1975-05-16 1977-01-25 Smithkline Corporation N-Heterocyclic-9-xanthenylamines
US4061753A (en) 1976-02-06 1977-12-06 Interx Research Corporation Treating psoriasis with transient pro-drug forms of xanthine derivatives
AU508480B2 (en) 1977-04-13 1980-03-20 Asahi Kasei Kogyo Kabushiki Kaisha Microcrystalline cellulose excipient and pharmaceutical composition containing thesame
DE2758025A1 (de) 1977-12-24 1979-07-12 Bayer Ag Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
DE2904885A1 (de) 1979-02-09 1980-08-14 Rothenberger Gmbh Co Biegevorrichtung fuer metallrohre
DE2929596A1 (de) 1979-07-21 1981-02-05 Hoechst Ag Verfahren zur herstellung von oxoalkyl-xanthinen
GB2084580B (en) 1980-10-01 1984-07-04 Glaxo Group Ltd Aminoalkyl furan derivative
US4382091A (en) 1981-04-30 1983-05-03 Syntex (U.S.A.) Inc. Stabilization of 1-substituted imidazole derivatives in talc
FR2558162B1 (fr) 1984-01-17 1986-04-25 Adir Nouveaux derives de la xanthine, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
FI79107C (fi) 1984-06-25 1989-11-10 Orion Yhtymae Oy Foerfarande foer framstaellning av stabil -form av prazosinhydroklorid.
JPS6130567A (ja) 1984-07-23 1986-02-12 Shiseido Co Ltd 尿素の安定化法
JPS61124383A (ja) 1984-11-16 1986-06-12 Unitika Ltd 固定化線維素溶解活性酵素の安定化法
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
CA1242699A (en) 1985-02-01 1988-10-04 Bristol-Myers Company Cefbuperazone and derivatives thereof
US4741898A (en) 1985-04-01 1988-05-03 Fisher Scientific Company Stabilized stain composition
GB8515934D0 (en) 1985-06-24 1985-07-24 Janssen Pharmaceutica Nv (4-piperidinomethyl and-hetero)purines
US5258380A (en) 1985-06-24 1993-11-02 Janssen Pharmaceutica N.V. (4-piperidinylmethyl and -hetero)purines
ES2058061T3 (es) 1985-10-25 1994-11-01 Beecham Group Plc Derivado de piperidina, su preparacion y su uso como medicamento.
US5034225A (en) 1985-12-17 1991-07-23 Genentech Inc. Stabilized human tissue plasminogen activator compositions
US5433959A (en) 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
EP0237608B1 (de) 1986-03-21 1992-01-29 HEUMANN PHARMA GMBH & CO Kristalline, wasserfreie Sigma -Form von 2-[4-(2-Furoyl-(2-piperazin)-1-yl]-4-amino-6,7-dimethoxychinazolinhydrochlorid und Verfahren zu ihrer Herstellung
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
DE3750402T3 (de) 1986-05-05 1997-04-10 Gen Hospital Corp Insulinotropes hormon.
AU619444B2 (en) 1986-06-02 1992-01-30 Nippon Chemiphar Co. Ltd. 2-(2-aminobenzylsulfinyl)- benzimidazole derivatives
US4968672A (en) 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPS6440433A (en) 1987-08-05 1989-02-10 Green Cross Corp Aqueous liquid composition of thrombin
DE68920773T2 (de) 1988-05-19 1995-05-18 Chugai Pharmaceutical Co Ltd Chinoloncarbonsäure-Derivate.
US5329025A (en) 1988-09-21 1994-07-12 G. D. Searle & Co. 3-azido compound
US5234897A (en) 1989-03-15 1993-08-10 Bayer Aktiengesellschaft Herbicidal 3-amino-5-aminocarbonyl-1,2,4-triazoles
DE3926119A1 (de) 1989-08-08 1991-02-14 Bayer Ag 3-amino-5-aminocarbonyl-1,2,4-triazol-derivate
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
DE3916430A1 (de) 1989-05-20 1990-11-22 Bayer Ag Verfahren zur herstellung von 3-amino-5-aminocarbonyl-1,2,4-triazol-derivaten
US5223499A (en) 1989-05-30 1993-06-29 Merck & Co., Inc. 6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists
IL94390A (en) 1989-05-30 1996-03-31 Merck & Co Inc The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them
US5332744A (en) 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
HU208115B (en) * 1989-10-03 1993-08-30 Biochemie Gmbh New process for producting pleuromutilin derivatives
FR2654935B1 (fr) 1989-11-28 1994-07-01 Lvmh Rech Utilisation de xanthines, eventuellement incorporees dans des liposomes, pour favoriser la pigmentation de la peau ou des cheveux.
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
KR930000861B1 (ko) 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
DE69104453T2 (de) 1990-09-13 1995-03-16 Akzo Nv Stabilisierte feste chemische Zusammensetzungen.
GB9020959D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
US5084460A (en) 1990-12-24 1992-01-28 A. H. Robins Company, Incorporated Methods of therapeutic treatment with N-(3-ouinuclidinyl)-2-hydroxybenzamides and thiobenzamides
US5591762A (en) * 1991-02-06 1997-01-07 Dr. Karl Thomae Gmbh Benzimidazoles useful as angiotensin-11 antagonists
US5602127A (en) 1991-02-06 1997-02-11 Karl Thomae Gmbh (Alkanesultam-1-yl)-benzimidazol-1-yl)-1yl)-methyl-biphenyls useful as angiotensin-II antagonists
US5594003A (en) * 1991-02-06 1997-01-14 Dr. Karl Thomae Gmbh Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
DE4124150A1 (de) 1991-07-20 1993-01-21 Bayer Ag Substituierte triazole
TW225528B (pt) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5300298A (en) 1992-05-06 1994-04-05 The Pennsylvania Research Corporation Methods of treating obesity with purine related compounds
GB9215633D0 (en) 1992-07-23 1992-09-09 Smithkline Beecham Plc Novel treatment
ATE165360T1 (de) 1992-07-31 1998-05-15 Shionogi & Co Triazolylthiomethylthiocephalosporin- hydrochlorid, sein kristallines hydrat und seine herstellung
TW252044B (pt) 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
DE4242459A1 (de) 1992-12-16 1994-06-23 Merck Patent Gmbh Imidazopyridine
WO1994015605A1 (en) 1993-01-14 1994-07-21 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
CA2118117A1 (en) 1993-02-18 1994-08-19 Shigeki Fujiwara Adenosine uptake inhibitor
JP3726291B2 (ja) 1993-07-05 2005-12-14 三菱ウェルファーマ株式会社 安定な結晶構造を有するベンゾオキサジン化合物およびその製造法
FR2707641B1 (fr) 1993-07-16 1995-08-25 Fournier Ind & Sante Composés de l'imidazol-5-carboxamide, leur procédé de préparation leurs intermédiaires et leur utilisation en thérapeutique.
DE4339868A1 (de) 1993-11-23 1995-05-24 Merck Patent Gmbh Imidazopyridazine
DE4404183A1 (de) 1994-02-10 1995-08-17 Merck Patent Gmbh 4-Amino-1-piperidylbenzoylguanidine
US5545745A (en) 1994-05-23 1996-08-13 Sepracor, Inc. Enantioselective preparation of optically pure albuterol
CO4410190A1 (es) 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
EP0785927B1 (en) 1994-10-12 2003-08-27 Euroceltique S.A. Novel benzoxazoles
GB9501178D0 (en) 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
US5821366A (en) 1995-05-19 1998-10-13 Chiroscience Limited Xanthines and their therapeutic use
SK72096A3 (en) 1995-06-06 1997-11-05 Pfizer Indole-2-carboxamides, glycogen phosphorylase inhibitors and pharmauceutical compositions
WO1996039384A1 (en) 1995-06-06 1996-12-12 Pfizer, Inc. Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
JPH08333339A (ja) 1995-06-08 1996-12-17 Fujisawa Pharmaceut Co Ltd 光学活性なピペリジン酢酸誘導体の製造法
GB9523752D0 (en) 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
DE19543478A1 (de) 1995-11-22 1997-05-28 Bayer Ag Kristallines Hydrochlorid von {(R)-(-)-2- N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-buytl]-aminomethyl}-chroman
FR2742751B1 (fr) 1995-12-22 1998-01-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
NZ326238A (en) 1995-12-26 1999-11-29 Alteon Inc Compositons and methods for inhibiting nonenzymatic cross-linking and glycosylation (protein aging) using N-acylaminoalkylhydrazine carboximidamides
US5891855A (en) 1996-02-12 1999-04-06 The Scripps Research Institute Inhibitors of leaderless protein export
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
AU1153097A (en) 1996-06-07 1998-01-05 Eisai Co. Ltd. Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production
US5965555A (en) 1996-06-07 1999-10-12 Hoechst Aktiengesellschaft Xanthine compounds having terminally animated alkynol side chains
US5958951A (en) 1996-06-14 1999-09-28 Novo Nordiskials Modified form of the R(-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride
US5753635A (en) 1996-08-16 1998-05-19 Berlex Laboratories, Inc. Purine derivatives and their use as anti-coagulants
CN1146567C (zh) 1996-09-23 2004-04-21 伊莱利利公司 奥氮平二水合物d
AU4699697A (en) 1996-10-28 1998-05-22 Novo Nordisk A/S A process for the preparation of (-)-3,4-trans-diarylchromans
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
ATE366584T1 (de) 1996-11-12 2007-08-15 Novo Nordisk As Verwendung von glp-1 peptiden
GB9623859D0 (en) 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
NZ336548A (en) 1996-12-24 2001-09-28 Biogen Inc Stable liquid interferon formulations comprising an amino acid as the stabilising agent
DE19705233A1 (de) 1997-02-12 1998-08-13 Froelich Juergen C Verfahren zur Herstellung einer Formulierung enthaltend Arginin
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
AU731186B2 (en) 1997-03-13 2001-03-29 Hexal Ag Stabilization of acid sensitive benzimidazols with amino acid/cyclodextrin combinations
US5972332A (en) 1997-04-16 1999-10-26 The Regents Of The University Of Michigan Wound treatment with keratinocytes on a solid support enclosed in a porous material
AR012894A1 (es) 1997-06-13 2000-11-22 Lilly Co Eli Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SK8402000A3 (en) 1997-12-05 2001-03-12 Astrazeneca Uk Ltd Novel compounds
ID21411A (id) 1997-12-10 1999-06-10 Takeda Chemical Industries Ltd Agen untuk mengobati daya tahan glukosa yang berisiko tinggi rusak
JPH11193270A (ja) 1997-12-26 1999-07-21 Koei Chem Co Ltd 光学活性１−メチル−３−ピペリジンメタノールの製造方法
AU1688599A (en) 1998-01-05 1999-07-26 Eisai Co. Ltd. Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes
CA2819705C (en) 1998-02-02 2014-07-08 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
US5998463A (en) 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
US20030013740A1 (en) 1998-03-27 2003-01-16 Martin P. Redmon Stable dosage forms of fluoxetine and its enantiomers
JP2002509919A (ja) 1998-03-31 2002-04-02 日産化学工業株式会社 ピリダジノン化合物塩酸塩及びその製造法
CA2268621A1 (en) 1998-04-13 1999-10-13 Takeda Chemical Industries, Ltd. 2-pipirazinone-1-acetic acid derivative, production and use thereof
US6207207B1 (en) 1998-05-01 2001-03-27 Mars, Incorporated Coated confectionery having a crispy starch based center and method of preparation
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
CN1185013C (zh) 1998-07-15 2005-01-19 旭化成株式会社 赋形剂
EP0978279A1 (en) 1998-08-07 2000-02-09 Pfizer Products Inc. Inhibitors of human glycogen phosphorylase
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
IT1312018B1 (it) 1999-03-19 2002-04-04 Fassi Aldo Procedimento migliorato per la produzione di sali non igroscopicidella l(-)-carnitina.
SI1169312T1 (en) 1999-03-29 2005-02-28 F. Hoffmann-La Roche Ag Glucokinase activators
WO2000066101A2 (en) 1999-04-30 2000-11-09 City Of Hope Method of inhibiting glycation product formation
AU4431000A (en) 1999-05-12 2000-12-05 Fujisawa Pharmaceutical Co., Ltd. Novel use
US20040152659A1 (en) 1999-05-12 2004-08-05 Fujisawa Pharmaceutical Co. Ltd. Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
AU5294100A (en) 1999-05-27 2000-12-18 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
DE60034445T2 (de) 1999-05-31 2008-01-03 Mitsubishi Chemical Corp. Gefriergetrocknete hgf-präparationen
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
WO2000072973A1 (en) 1999-06-01 2000-12-07 Elan Pharma International Ltd. Small-scale mill and method thereof
EE04748B1 (et) 1999-06-21 2006-12-15 Boehringer Ingelheim Pharma Kg Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetodid nende valmistamiseks
US6448323B1 (en) 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
ES2166270B1 (es) 1999-07-27 2003-04-01 Almirall Prodesfarma Sa Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
ES2216937T3 (es) 1999-08-31 2004-11-01 Kissei Pharmaceutical Co., Ltd. Derivados de glucopiranosiloxipirazol, composiciones medicinales que los contienen e intermedios obtenidos durante su preparacion.
EP1220832A1 (en) 1999-09-29 2002-07-10 Novo Nordisk A/S Novel aromatic compounds
EP1391460A1 (en) 1999-09-30 2004-02-25 Pfizer Products Inc. Tricyclic pyrrolyl amides as glycogen phosphorylase inhibitors
PT1088824E (pt) 1999-09-30 2004-04-30 Pfizer Prod Inc Pirrolil-amidas biciclicas como inibidores de glicogenio-fosforilase
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
GB9928330D0 (en) 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
AU777776B2 (en) 1999-12-23 2004-10-28 Novartis Ag Use of hypoglycemic agent for treating impaired glucose metabolism
CA2396079A1 (en) 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US6362172B2 (en) 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
PT1741445E (pt) 2000-01-21 2013-11-11 Novartis Ag Combinações incluindo inibidores de dipeptidilpeptidase-iv e agentes antidiabéticos
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
JP4621326B2 (ja) 2000-02-01 2011-01-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 テプレノンの安定化組成物
WO2001056993A2 (en) 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
EP1295609A4 (en) 2000-02-24 2004-11-03 Takeda Chemical Industries Ltd DRUGS CONTAINING COMBINED ACTIVE INGREDIENTS
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
MXPA02009034A (es) 2000-03-17 2003-09-10 Kissei Pharmaceutical Derivados de glucopiranosiloxibencilbenceno, composiciones medicinales conteniendo los mismos e intermediarios para la preparacion de los derivados.
EP1136071A3 (en) 2000-03-22 2003-03-26 Pfizer Products Inc. Use of glycogen phosphorylase inhibitors
JP2001278812A (ja) 2000-03-27 2001-10-10 Kyoto Pharmaceutical Industries Ltd 錠剤用崩壊剤及びこれを用いた錠剤
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
EP1273306A4 (en) 2000-03-31 2005-06-22 Kirin Brewery POWDER PREPARATION INTENDED FOR MUCOUS MEMBRANES COMPRISING A POLYMERIC MEDICAMENT HAVING IMPROVED STORAGE STABILITY
CZ20023234A3 (cs) 2000-03-31 2003-01-15 Probiodrug Ag Léčivo proti diabetu
JP2001292388A (ja) 2000-04-05 2001-10-19 Sharp Corp 再生装置
GB0008694D0 (en) 2000-04-07 2000-05-31 Novartis Ag Organic compounds
CN1209361C (zh) 2000-05-03 2005-07-06 霍夫曼-拉罗奇有限公司 含乙内酰脲的葡糖激酶激活剂
US6388071B2 (en) 2000-05-03 2002-05-14 Hoffmann-La Roche Inc. Alkynyl phenyl heteroaromatic glucokinase activators
DE60134470D1 (de) 2000-05-08 2008-07-31 Hoffmann La Roche Para-amin substituierte phenylamid glukokinase activatoren
ES2230309T3 (es) 2000-05-08 2005-05-01 F. Hoffmann-La Roche Ag Fenilacetamidas sustituidas y su empleo con ativadores de qucokinasa.
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
ATE265424T1 (de) 2000-06-09 2004-05-15 Aventis Pharma Gmbh Acylphenylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US6962998B2 (en) 2000-06-14 2005-11-08 Toray Industries, Inc. Processes for producing racemic piperidine derivative and for producing optically active piperidine derivative
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US7078397B2 (en) 2000-06-19 2006-07-18 Smithkline Beecham Corporation Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
MXPA02012272A (es) 2000-07-04 2003-04-25 Novo Nordisk As Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv.
EP1305301B1 (en) 2000-07-20 2005-06-15 F. Hoffmann-La Roche Ag Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators
ATE411285T1 (de) 2000-08-10 2008-10-15 Mitsubishi Tanabe Pharma Corp Prolin-derivate und deren verwendung als medikamente
US6369232B1 (en) 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
GB0021831D0 (en) 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
EP1329456B1 (en) 2000-09-29 2006-08-09 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
WO2002036602A1 (fr) 2000-11-02 2002-05-10 Ajinomoto Co., Inc. Nouveaux derives du pyrazole et remedes au diabete contenant ces derniers
US20060034922A1 (en) 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
US6722883B2 (en) 2000-11-13 2004-04-20 G & H Technologies Llc Protective coating for abrasive dental tools and burs
US7053060B2 (en) 2000-11-30 2006-05-30 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
JP4109111B2 (ja) 2000-12-06 2008-07-02 エフ．ホフマン−ラ ロシュ アーゲー 縮合複素環式芳香族グルコキナーゼアクチベーター
US6821261B2 (en) 2000-12-12 2004-11-23 Dj Orthopedics, Llc Orthopedic brace having length-adjustable supports
US6482951B2 (en) 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
EP1354882A1 (en) 2000-12-27 2003-10-22 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
WO2002053573A1 (fr) 2000-12-28 2002-07-11 Kissei Pharmaceutical Co., Ltd. Derives de glucopyranosiloxypyrazole et leur utilisation dans des medicaments
FR2818906B1 (fr) 2000-12-29 2004-04-02 Dospharma Association medicamenteuse d'une biguanine et d'un transporteur, par exemple de metformine et d'arginine
FR2819254B1 (fr) 2001-01-08 2003-04-18 Fournier Lab Sa Nouveaux composes de la n-(phenylsulfonyl) glycine, leur procede de preparation et leur utilisation pour obtenir des compostions pharmaceutiques
DE10109021A1 (de) 2001-02-24 2002-09-05 Boehringer Ingelheim Pharma Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10117803A1 (de) 2001-04-10 2002-10-24 Boehringer Ingelheim Pharma Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
WO2002062764A1 (en) 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Fused heterocyclic compounds
TWI255817B (en) 2001-02-14 2006-06-01 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
US6610326B2 (en) 2001-02-16 2003-08-26 Andrx Corporation Divalproex sodium tablets
US6649187B2 (en) 2001-02-16 2003-11-18 Bristol-Myers Squibb Pharma Company Use of polyalkylamine polymers in controlled release devices
ES2444772T3 (es) 2001-02-24 2014-02-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Derivados de xantina, su preparación y uso como medicamentos
CA2438593C (en) 2001-02-26 2010-09-21 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and medicinal use thereof
ES2350084T3 (es) 2001-02-27 2011-01-18 Kissei Pharmaceutical Co., Ltd. Derivados de glucopiranosiloxipirazol y uso médico de los mismos.
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6693094B2 (en) * 2001-03-22 2004-02-17 Chrono Rx Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
GB0107383D0 (en) 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
US6774112B2 (en) 2001-04-11 2004-08-10 Bristol-Myers Squibb Company Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
EP1389621A4 (en) 2001-04-27 2005-05-11 Ajinomoto Kk N-SUBSTITUTED PYRAZOLYL-O-GLYCOSIDE DERIVATIVES AND DIABETES CONTAINING THEREOF
JP2002348279A (ja) 2001-05-25 2002-12-04 Nippon Kayaku Co Ltd 光学活性ピリジルケトン誘導体の製造方法並びに光学活性ピリジルケトン誘導体
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
WO2002098893A1 (en) 2001-05-30 2002-12-12 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
CA2455300A1 (en) 2001-06-20 2003-01-03 Kissei Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
DE10130371A1 (de) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
US6901589B2 (en) * 2001-06-25 2005-05-31 Wind River Systems, Inc. System and method for determining a root cause of a failure
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102300D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
JP4357293B2 (ja) 2001-06-27 2009-11-04 スミスクライン ビーチャム コーポレーション ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
BR0210644A (pt) 2001-06-27 2004-07-20 Smithkline Beecham Corp Composto, formulação farmacêutica, método para inibir uma protease que cliva pós prolina/alanina, método para o tratamento ou profilaxia de distúrbios, e, uso do composto
JP4115105B2 (ja) 2001-07-02 2008-07-09 協和醗酵工業株式会社 ピラゾール誘導体
JP2005502624A (ja) 2001-07-03 2005-01-27 ノボ　ノルディスク　アクティーゼルスカブ 糖尿病を治療するための、ｄｐｐ−ｉｖを阻害するプリン誘導体
US6869947B2 (en) 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
MXPA04000224A (es) 2001-07-10 2005-07-25 4Sc Ag Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
WO2003011880A1 (fr) 2001-07-31 2003-02-13 Kissei Pharmaceutical Co., Ltd. Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US20030087843A1 (en) 2001-09-05 2003-05-08 Washburn William N. O-pyrazole glucoside SGLT2 inhibitors and method of use
JPWO2003024942A1 (ja) 2001-09-14 2004-12-24 三菱ウェルファーマ株式会社 チアゾリジン誘導体およびその医薬用途
JP2005509603A (ja) 2001-09-19 2005-04-14 ノボ　ノルディスク　アクティーゼルスカブ Ｄｐｐ−ｉｖ酵素の阻害剤であるヘテロ環化合物
AU2002353784B2 (en) 2001-09-24 2008-04-10 Oregon Health And Science University Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior
DK1435877T3 (da) 2001-10-15 2009-08-03 Hemoteq Ag Overtrækning af stents for at forhindre restenose
DE10151296A1 (de) 2001-10-17 2003-04-30 Boehringer Ingelheim Pharma Keratinozyten verwendbar als biologisch aktive Substanz bei der Behandlung von Wunden
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030083354A1 (en) 2001-10-26 2003-05-01 Pediamed Pharmaceuticals, Inc. Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
CA2465382A1 (en) 2001-10-29 2003-05-08 Japan Tobacco Inc. Indole compound and medicinal use thereof
CA2464995A1 (en) * 2001-10-31 2003-05-08 Novartis Ag Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
CA2363053C (en) 2001-11-09 2011-01-25 Bernard Charles Sherman Clopidogrel bisulfate tablet formulation
WO2003044000A1 (en) 2001-11-22 2003-05-30 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
PL370111A1 (en) 2001-11-22 2005-05-16 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
KR20050044517A (ko) 2001-11-22 2005-05-12 바이오비트럼 에이비 11-베타-히드록시 스테로이드 탈수소효소 유형 1 의억제제
JP2005511636A (ja) 2001-11-26 2005-04-28 トラスティーズ オブ タフツ カレッジ 自己免疫疾患の治療方法及びそれに関する試薬
AU2002349299A1 (en) 2001-12-03 2003-06-17 Novo Nordisk A/S Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
KR20040064687A (ko) 2001-12-21 2004-07-19 도오레 화인케미칼 가부시키가이샤 광학 활성 시스 피페리딘 유도체의 제조법
AU2002361861A1 (en) 2001-12-21 2003-07-30 Rhode Island Hospital SELECTIVE 11Beta-HSD INHIBITORS AND METHODS FOR USE THEREOF
IL162620A0 (en) 2001-12-21 2005-11-20 Novo Nordisk As Amide derivatives as gk activators
US6727261B2 (en) 2001-12-27 2004-04-27 Hoffman-La Roche Inc. Pyrido[2,1-A]Isoquinoline derivatives
EP1466621A4 (en) 2001-12-28 2009-05-27 Nrl Pharma Inc COMPOSITIONS FOR ENHANCING LIPID METABOLISM
CA2472882A1 (en) 2002-01-10 2003-07-17 Imperial College Innovations Ltd Use of pyy and glp-1, or an agonist thereof, for the modification of feeding behaviour
US20070197552A1 (en) 2002-01-11 2007-08-23 Novo Nordisk A/S Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
DE60323823D1 (de) 2002-01-11 2008-11-13 Novo Nordisk As Verfahren und zusammensetzung zur behandlung von diabetes, hypertonie, chronischer herzinsuffizienz und mit flüssigkeitsretention einhergehenden zuständen
CZ303145B6 (cs) 2002-01-16 2012-05-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Zpusob výroby dvojvrstevné farmaceutické tablety obsahující telmisartan a hydrochlorthiazid
CA2472205A1 (en) 2002-01-18 2003-07-24 Frank Robert Busch Intermediates for preparing glycogen phosphorylase inhibitors
CA2476984C (en) 2002-01-21 2013-12-10 Nrl Pharma, Inc. Lactoferrin as an agent for enhancing action of an opioid
EP1333033A1 (en) 2002-01-30 2003-08-06 Boehringer Ingelheim Pharma GmbH & Co.KG FAP-activated anti-tumor compounds
EP1469829B1 (en) 2002-02-01 2016-01-27 Bend Research, Inc Immediate release dosage forms containing solid drug dispersions
EP1474139B1 (en) 2002-02-01 2007-11-21 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
US7610153B2 (en) 2002-02-13 2009-10-27 Virginia Commonwealth University Multi-drug titration and evaluation
AU2003211146B2 (en) 2002-02-21 2007-07-19 Valeant International (Barbados) Srl Controlled release dosage forms
EP1338595B1 (en) 2002-02-25 2006-05-03 Eisai Co., Ltd. Xanthine derivatives as DPP-IV inhibitors
MXPA03000966A (es) 2002-02-28 2003-09-04 Pfizer Prod Inc Agentes antidiabeticos.
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
HUP0200849A2 (hu) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
KR100945455B1 (ko) 2002-03-22 2010-03-05 깃세이 야쿠힌 고교 가부시키가이샤 글루코피라노실옥시벤질 벤젠 유도체의 결정
JP4419571B2 (ja) 2002-03-26 2010-02-24 萬有製薬株式会社 新規アミノベンズアミド誘導体
JP4298212B2 (ja) 2002-03-29 2009-07-15 大日本印刷株式会社 塩酸エピナスチン高融点型結晶の製造法
JP2003300977A (ja) 2002-04-10 2003-10-21 Sumitomo Pharmaceut Co Ltd キサンチン誘導体
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
IL164249A0 (en) 2002-04-11 2005-12-18 Aventis Pharma Gmbh Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
US6683106B2 (en) 2002-04-15 2004-01-27 Pfizer Inc. N-(indole-2-carbonyl)-b-alaninamide crystal forms
CA2480325A1 (en) 2002-04-16 2003-10-30 Merck & Co., Inc. Solid forms of salts with tyrosine kinase activity
WO2003091213A1 (fr) 2002-04-25 2003-11-06 Yamanouchi Pharmaceutical Co., Ltd. Derives d'amide ou sels de ces derives
ES2276097T3 (es) 2002-04-26 2007-06-16 F. Hoffmann-La Roche Ag Fenilacetamidas sustituidas y su empleo0 como activadores de glucoquinasa.
CA2484306A1 (en) 2002-04-26 2003-11-06 Katsumi Maezono Prophylactic and therapeutic agent of diabetes mellitus
AU2003231252A1 (en) 2002-05-09 2003-11-11 Enos Pharmaceuticals, Inc. Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
GB2388594A (en) * 2002-05-16 2003-11-19 Bayer Ag Imidazo-triazine PDE 4 inhibitors
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
CN101538224A (zh) 2002-05-31 2009-09-23 先灵公司 制备黄嘌呤磷酸二酯酶v抑制剂及其前体的方法
KR100985160B1 (ko) 2002-06-06 2010-10-05 에자이 알앤드디 매니지먼트 가부시키가이샤 신규한 축합된 이미다졸 유도체
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
ES2199061B1 (es) 2002-06-10 2005-02-16 Laboratorios Vita, S.A. Comprimidos bucodispersables y procedimiento para su obtencion.
FR2840897B1 (fr) 2002-06-14 2004-09-10 Fournier Lab Sa Nouveaux derives d'arylsulfonamides et leur utilisation en therapeutique
EP2471533A1 (en) 2002-06-27 2012-07-04 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
US20040002615A1 (en) 2002-06-28 2004-01-01 Allen David Robert Preparation of chiral amino-nitriles
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
MXPA05000055A (es) 2002-07-11 2005-04-08 Aventis Pharma Gmbh Acilureas sustituidas con urea y uretano, metodos para su produccion y su uso.
DE50312261D1 (de) 2002-07-12 2010-02-04 Sanofi Aventis Deutschland Heterozyklisch substituierte benzoylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US20040023981A1 (en) 2002-07-24 2004-02-05 Yu Ren Salt forms with tyrosine kinase activity
TW200409746A (en) 2002-07-26 2004-06-16 Theravance Inc Crystalline β2 adrenergic receptor agonist
BR0312957A (pt) 2002-07-27 2005-06-14 Astrazeneca Ab Composto ou um sal farmaceuticamente aceitável deste, uso do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, em necessidade de tal tratamento
TWI254635B (en) 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
MXPA05001549A (es) 2002-08-08 2005-05-05 Kissei Pharmaceutical Derivado de pirazol, composicion medicinal que lo contiene, su uso medicinal, e intermediario para su produccion.
CA2478889A1 (en) 2002-08-09 2004-02-19 Taisho Pharmaceutical Co., Ltd. Aryl 5-thio-.beta.-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
TW200404796A (en) 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
DE10238243A1 (de) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP2308878A3 (de) * 2002-08-21 2011-10-26 Boehringer Ingelheim Pharma GmbH & Co. KG 8-[3-Amino-Piperidin-1-YL] -Xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE10238477A1 (de) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10238470A1 (de) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7495005B2 (en) 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
JP4606876B2 (ja) 2002-08-27 2011-01-05 キッセイ薬品工業株式会社 ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
EP1537880A4 (en) 2002-09-11 2009-07-01 Takeda Pharmaceutical PREPARATION FOR PROLONGED RELEASE
BR0314356A (pt) 2002-09-16 2005-07-19 Wyeth Corp Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas
US7262207B2 (en) 2002-09-19 2007-08-28 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
NZ538936A (en) 2002-09-26 2006-12-22 Eisai Co Ltd Combination drug comprising a combination of a dipeptidyl peptidase IV (DPPIV) inhibitor with biguanide
NZ539013A (en) 2002-10-03 2007-05-31 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
CA2499329C (en) 2002-10-03 2009-04-21 F. Hoffmann-La Roche Ag Indole-3-carboxamides as glucokinase (gk) activators
DE10246434B4 (de) 2002-10-04 2005-08-04 Aventis Pharma Deutschland Gmbh Carboxyalkoxy-substituierte Acyl-carboxyphenyl-harnstoffderivate und ihre Verwendung als Arzneimittel
AU2003269850A1 (en) 2002-10-08 2004-05-04 Novo Nordisk A/S Hemisuccinate salts of heterocyclic dpp-iv inhibitors
EP1558218A1 (en) 2002-10-08 2005-08-03 Ranbaxy Laboratories Limited Gabapentin tablets and methods for their preparation
US20040122048A1 (en) * 2002-10-11 2004-06-24 Wyeth Holdings Corporation Stabilized pharmaceutical composition containing basic excipients
BR0315166A (pt) 2002-10-11 2005-08-16 Astrazeneca Ab Uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, que necessita de tratamento
US6861526B2 (en) 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
DE60320008T2 (de) 2002-10-18 2009-06-18 Merck & Co., Inc. Heterozyklische beta-aminoverbindungen als inhibitoren des dipeptidylpeptidase zur behandlung bzw. prevention von diabetes
JP2004161749A (ja) 2002-10-24 2004-06-10 Toray Fine Chemicals Co Ltd 光学活性含窒素化合物の製造方法
EP1556040A1 (en) 2002-10-24 2005-07-27 Sterix Limited Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2
JP2006507359A (ja) 2002-10-28 2006-03-02 ノボ・ノルデイスク・エー／エス 心循環器疾患の治療のためのグリコーゲンホスホリラーゼ阻害剤の使用
AU2003280680A1 (en) 2002-11-01 2004-06-18 Sumitomo Pharmaceuticals Co., Ltd. Xanthine compound
JP4413863B2 (ja) 2002-11-07 2010-02-10 メルク エンド カムパニー インコーポレーテッド 糖尿病の治療又は予防のためのジペチジルペプチダーゼ阻害剤としてのフェニルアラニン誘導体
BR0316099A (pt) 2002-11-07 2005-09-27 Pfizer Prod Inc Agentes antidiabéticos
AU2003276458A1 (en) 2002-11-07 2004-06-07 Astrazeneca Ab 2-oxo-ethanesulfonamide derivates
DE10251927A1 (de) 2002-11-08 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7109192B2 (en) * 2002-12-03 2006-09-19 Boehringer Ingelheim Pharma Gmbh & Co Kg Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
UY28103A1 (es) * 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
JP4651934B2 (ja) 2002-12-04 2011-03-16 キッセイ薬品工業株式会社 ベンジルフェノール誘導体、それを含有する医薬組成物およびその医薬用途
CA2505771A1 (en) 2002-12-10 2004-06-24 Novartis Ag Combination of an dpp-iv inhibitor and a ppar-alpha compound
PE20040801A1 (es) 2002-12-12 2004-11-25 Hoffmann La Roche Derivados de pirazina y piridina 5-sustituidos como activadores de glucoquinasa
DE10258008B4 (de) 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
JP2004196702A (ja) 2002-12-18 2004-07-15 Yamanouchi Pharmaceut Co Ltd 新規なアミド誘導体又はその塩
DE10351663A1 (de) 2002-12-20 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverförmige Arzneimittel enthaltend ein Tiotropiumsalz und Salmeterolxinafoat
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
US20040152720A1 (en) 2002-12-20 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powdered medicaments containing a tiotropium salt and salmeterol xinafoate
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
AU2003289440A1 (en) 2002-12-25 2004-07-22 Kissei Pharmaceutical Co., Ltd. Nitrogen-containing heterocycic derivatives, medicinal compositions containing the same and medicinal use thereof
CA2509086C (en) 2003-01-06 2012-08-21 Eli Lilly And Company Substituted arylcyclopropylacetamides as glucokinase activators
AU2003294376A1 (en) 2003-01-06 2004-08-10 Eli Lilly And Company Heteroaryl compounds
SI1599222T1 (sl) 2003-01-08 2009-08-31 Novartis Vaccines & Diagnostic Stabilizirani vodni sestavki, ki obsegajo inhibitor poti tkivnega faktorja (TFPI) ali varianto inhibitorja poti tkivnega faktorja
NZ540612A (en) 2003-01-14 2008-02-29 Arena Pharm Inc 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
DE10302452B4 (de) 2003-01-23 2005-02-24 Aventis Pharma Deutschland Gmbh Carbonylamino-substituierte Acyl-phenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
EP1594863A1 (en) 2003-02-11 2005-11-16 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
MXPA05008619A (es) 2003-02-13 2005-11-04 Banyu Pharma Co Ltd Derivados novedosos de 2-piridincarboxamida.
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
DE10306502B4 (de) 2003-02-17 2005-03-17 Aventis Pharma Deutschland Gmbh Substituierte 3-(Benzoylureido)-thiophenderivate und sie enthaltende Arzneimittel
JP2004250336A (ja) 2003-02-18 2004-09-09 Kao Corp コーティング錠及び糖衣錠の製造法
US7432287B2 (en) 2003-02-26 2008-10-07 Banyu Pharmeceutical Co., Ltd. Heteroarylcarbamoylbenzene derivative
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7442387B2 (en) 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
DE10309929B4 (de) 2003-03-07 2006-02-23 Sanofi-Aventis Deutschland Gmbh Substituierte Benzoylureidopyridyl-piperidin- und -pyrrolidin-carbonsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
MXPA05009564A (es) 2003-03-12 2005-11-17 Univ Arizona Sales de bases debiles.
RU2317288C3 (ru) 2003-03-14 2021-03-10 Астеллас Фарма Инк. С-гликозидные производные и их соли
CA2516142A1 (en) 2003-03-18 2004-09-30 Novartis Ag Compositions comprising fatty acids and amino acids
JP2004300102A (ja) 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
JPWO2004089966A1 (ja) 2003-04-01 2006-07-06 大正製薬株式会社 選択的なヘテロアリール５−チオ−β−Ｄ−アルドヘキソピラノシドの製造法
ES2528669T3 (es) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
EP1615697A2 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof
ES2338656T3 (es) 2003-04-11 2010-05-11 High Point Pharmaceuticals, Llc Uso farmaceutico de 1,2,4-triazoles fusionados.
EP1615637A1 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
JP4629657B2 (ja) 2003-04-11 2011-02-09 ハイ・ポイント・ファーマスーティカルズ、エルエルシー １１β−ヒドロキシステロイドデヒドロゲナーゼ１型化活性化合物
WO2004092158A1 (en) 2003-04-17 2004-10-28 Pfizer Products Inc. Carboxamide derivatives as anti-diabetic agents
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
WO2004096806A1 (ja) 2003-04-30 2004-11-11 Sumitomo Pharmaceuticals Co. Ltd. 縮合イミダゾール誘導体
MXPA05011702A (es) 2003-04-30 2006-01-23 Pfizer Prod Inc Agentes antidiabeticos.
AU2003902263A0 (en) 2003-05-12 2003-05-29 Fujisawa Pharmaceutical Co., Ltd. Monosaccharide compounds
NZ543482A (en) 2003-05-21 2009-02-28 Prosidion Ltd Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phoshorylase
EP1631558A1 (en) 2003-05-21 2006-03-08 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i
TW200510277A (en) 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist
FR2855521B1 (fr) 2003-05-28 2005-08-05 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques.
DE602004028473D1 (de) 2003-05-29 2010-09-16 Merck Sharp & Dohme Triazolderivate als inhibitoren von 11-beta- hydroxysteroid-dehydrogenase-1
AU2003902828A0 (en) 2003-06-05 2003-06-26 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
JP2004359630A (ja) 2003-06-06 2004-12-24 Yamanouchi Pharmaceut Co Ltd ジフルオロジフェニルメタン誘導体及びその塩
US7566707B2 (en) 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10327439A1 (de) 2003-06-18 2005-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel
WO2004113345A1 (ja) 2003-06-20 2004-12-29 Japan Tobacco Inc. 縮合ピロール化合物及びその医薬用途
CN101090901B (zh) 2003-06-20 2010-12-15 霍夫曼-拉罗奇有限公司 作为dpp-iv抑制剂的六氢吡啶并异喹啉类
CA2529878C (en) 2003-06-20 2012-11-20 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, drug composition containing the same and production intermediate therefor
EA009591B1 (ru) * 2003-06-20 2008-02-28 Ф.Хоффманн-Ля Рош Аг Производные пиридо[2,1-а]изохинолина в качестве ингибиторов dpp-iv
JO2625B1 (en) 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salts of dipeptidyl betidase inhibitor 4
WO2004113310A1 (en) 2003-06-25 2004-12-29 Biovitrum Ab Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing
US7364755B2 (en) 2003-07-07 2008-04-29 Synthon Ip Inc. Modified calcium phosphate excipient
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
TWI335328B (en) 2003-07-14 2011-01-01 Arena Pharm Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related hereto
US20050027012A1 (en) 2003-07-16 2005-02-03 Boehringer Ingelheim International Gmbh Tablets containing ambroxol
ATE457166T1 (de) 2003-07-24 2010-02-15 Wockhardt Ltd Orale zusammensetzungen zur behandlung von diabetes
BRPI0413234A (pt) 2003-08-01 2006-10-03 Genelabs Tech Inc derivados de imidazola bicìclica contra flaviviridae
DE10335092B3 (de) 2003-08-01 2005-02-03 Aventis Pharma Deutschland Gmbh Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
EP1651658B2 (en) 2003-08-01 2020-08-12 Mitsubishi Tanabe Pharma Corporation Novel compounds having inhibitory activity against sodium-dependant transporter
EA010422B1 (ru) 2003-08-01 2008-08-29 Янссен Фармацевтика Н.В. Замещённые индол-о-глюкозиды
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
EP1679965A4 (en) 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES
EP1679966A4 (en) 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv BENZIMIDAZOLE-, BENZTRIAZOLE- AND BENZIMIDAZOLONE-SUBSTITUTED O-GLUCOSIDES
EP1680414A4 (en) 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv SUBSTITUTED INDAZOLE-O-GLUCOSIDE
JP2007501789A (ja) 2003-08-07 2007-02-01 メルク　エンド　カムパニー　インコーポレーテッド １１−β−ヒドロキシステロイドデヒドロゲナーゼ−１の阻害剤としてのピラゾールカルボキサミド
GB0318464D0 (en) 2003-08-07 2003-09-10 Astrazeneca Ab Chemical compounds
GB0318463D0 (en) 2003-08-07 2003-09-10 Astrazeneca Ab Chemical compounds
KR101293503B1 (ko) 2003-08-14 2013-08-07 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물
GB0319690D0 (en) 2003-08-22 2003-09-24 Astrazeneca Ab Chemical compounds
GB0319759D0 (en) 2003-08-22 2003-09-24 Astrazeneca Ab Chemical compounds
CA2539032A1 (en) 2003-08-26 2005-03-10 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pirazoles, drugs containing said compounds the use and production method thereof
WO2005020986A1 (en) 2003-08-29 2005-03-10 Astrazeneca Ab Heterocyclic amide derivatives which posses glycogen phosphorylase inhibitory activity
AU2004270150C1 (en) 2003-08-29 2011-07-14 Merck Hdac Research, Llc Combination methods of treating cancer
WO2005020985A1 (en) 2003-08-29 2005-03-10 Astrazeneca Ab Indolamide derivatives which possess glycogen phosphorylase inhibitory activity
GB0320422D0 (en) 2003-08-30 2003-10-01 Astrazeneca Ab Chemical compounds
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
ATE534404T1 (de) 2003-10-03 2011-12-15 Takeda Pharmaceutical Dipeptidylpeptidase-iv-inhibitoren zur behandlung von diabetes-patienten mit sekundärversagen durch sulfonylharnstoffe
US7284625B2 (en) 2003-10-22 2007-10-23 Kirk Jones Quick connect assembly for ATV implements
CA2540843A1 (en) 2003-10-23 2005-05-12 Sterix Limited Phenyl carboxamide and sulfonamide derivatives for use as 11-beta-hydroxysteroid dehydrogenase
US20050091394A1 (en) 2003-10-27 2005-04-28 Schneider Automation Inc. Software configurable dual cable redundant Ethernet or bus configuration
US7246174B2 (en) 2003-10-28 2007-07-17 Nacon Consulting, Llc Method and system for accessing and managing virtual machines
BR0304443B1 (pt) 2003-10-28 2012-08-21 processo para obtenção de concentrados de titánio com elevado teor de tio2 e baixo teor de radionuclìdeos a partir de concentrados mecánicos de anatásio.
AU2004286836A1 (en) 2003-10-28 2005-05-19 Amgen Inc. Triazole compounds and uses related thereto
GB0325402D0 (en) 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
GB0325745D0 (en) 2003-11-05 2003-12-10 Astrazeneca Ab Chemical compounds
GB0326029D0 (en) 2003-11-07 2003-12-10 Astrazeneca Ab Chemical compounds
US7107714B2 (en) 2003-11-10 2006-09-19 Marketing Displays, Inc. Portable snap-fit sign stand
KR20060109911A (ko) * 2003-11-17 2006-10-23 노파르티스 아게 디펩티딜 펩티다제 ⅳ 억제제의 용도
JP2005170939A (ja) 2003-11-20 2005-06-30 Takeda Chem Ind Ltd 糖尿病の予防・治療剤
EP1532980A1 (en) 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
DE10355304A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
GB0327760D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
GB0327761D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
WO2005053695A1 (ja) 2003-12-04 2005-06-16 Eisai Co., Ltd. 多発性硬化症予防剤または治療剤
GB0328178D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Compounds
DE10359098A1 (de) 2003-12-17 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-(Piperazin-1-yl)- und 2-([1,4]Diazepan-1-yl)-imidazo[4,5-d]pyridazin-4-one, deren Herstellung und deren Verwendung als Arzneimittel
US7217711B2 (en) 2003-12-17 2007-05-15 Boehringer Ingelheim International Gmbh Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions
ATE501135T1 (de) 2003-12-18 2011-03-15 Tibotec Pharm Ltd Piperidinamino-benzimidazol-derivate al respiratorisches syncytialvirus replikation inhibitoren
EA200600990A1 (ru) 2003-12-19 2006-10-27 Пфайзер Инк. Производные бензосульфониламинопиридин-2-ила и родственные соединения в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы 1 типа (11-бета-hsd-1) для лечения диабета и ожирения
DE10361133A1 (de) 2003-12-22 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Glucopyranosyloxy-substituierte Aromaten, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP1703908A4 (en) 2003-12-22 2009-07-08 Amgen Inc ARYLSULFONAMIDE COMPOUNDS AND RELATED APPLICATIONS
DE10360835A1 (de) 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
CA2549955A1 (en) 2003-12-24 2005-07-07 Prosidion Limited Heterocyclic derivatives as gpcr receptor agonists
AU2004309287B2 (en) 2003-12-29 2008-07-31 Banyu Pharmaceutical Co., Ltd Novel 2-heteroaryl-substituted benzimidazole derivative
JP2007517800A (ja) 2004-01-06 2007-07-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 糖尿病および肥満を処置するためのグリコーゲンホスホリラーゼインヒビターとしての（３−オキソ−３，４−ジヒドロ−キノキサリン−２−イル−アミノ）−ベンズアミド誘導体および関連化合物
PL1723128T3 (pl) 2004-01-06 2013-04-30 Novo Nordisk As Pochodne heteroarylowe mocznika oraz ich zastosowanie jako aktywatory glukokinazy
WO2005070390A2 (en) 2004-01-21 2005-08-04 Janssen Pharmaceutica N.V. Mitratapide oral solution
IN2012DN03023A (pt) 2004-01-26 2015-07-31 Merck Sharp & Dohme
DE102004004972B3 (de) 2004-01-31 2005-09-15 Aventis Pharma Deutschland Gmbh Heterocyclisch substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2005073229A1 (de) 2004-01-31 2005-08-11 Sanofi-Aventis Deutschland Gmbh 7-phenylamino-4-chinolon-3-carbonsäure-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE102004004971B3 (de) 2004-01-31 2005-09-15 Aventis Pharma Deutschland Gmbh Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel
US20050239853A1 (en) 2004-02-04 2005-10-27 Tjeerd Barf New compounds
JP2005247834A (ja) 2004-02-04 2005-09-15 Taisho Pharmaceut Co Ltd ナトリウム依存性グルコース供輸送体２の活性阻害剤
SE0400234D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New compounds, methods for their preparation and use thereof
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
EP1718625A1 (en) 2004-02-18 2006-11-08 AstraZeneca AB Compounds
EP1758905B1 (de) * 2004-02-18 2009-04-29 Boehringer Ingelheim International GmbH 8-[3-amino-piperidin-1-yl]-xanthine, deren herstellung und deren verwendung als dpp-iv hemmer
EP2048137A1 (en) 2004-02-18 2009-04-15 AstraZeneca AB Benzamide derivatives and their use as glucokinase activating agents.
DE102004019540A1 (de) 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen
DE102004009039A1 (de) 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7732596B2 (en) 2004-03-04 2010-06-08 Kissei Pharmaceutical Co., Ltd. Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
EP1724278B1 (en) 2004-03-04 2014-05-07 Kissei Pharmaceutical Co., Ltd. Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
JP4950657B2 (ja) 2004-03-04 2012-06-13 キッセイ薬品工業株式会社 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
EP1593671A1 (en) 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG DPP-IV inhibitors
EP1725555B1 (en) 2004-03-08 2010-10-06 Prosidion Ltd. Pyrrolopyridine-2-carboxylic acid hydrazides as inhibitors of glycogen phosphorylase
WO2005085194A2 (en) 2004-03-08 2005-09-15 Prosidion Limited Indole-2-carboxylic acid hydrazides as glycogen phosphorylase inhibitors
US7393847B2 (en) 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
CN102134230B (zh) 2004-03-15 2019-06-28 武田药品工业株式会社 二肽基肽酶抑制剂
EA011158B1 (ru) 2004-03-16 2009-02-27 Бёрингер Ингельхайм Интернациональ Гмбх Замещённые глюкопиранозилом бензольные производные, содержащие эти соединения лекарственные средства, их применение и способ их получения
EP1577306A1 (de) 2004-03-17 2005-09-21 Boehringer Ingelheim Pharma GmbH & Co.KG Neue Benzoxazinonderivate als langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
CA2560286A1 (en) 2004-03-23 2005-09-29 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
US7354938B2 (en) 2004-03-23 2008-04-08 Amgen Inc. Pyrazole compounds and uses related thereto
JP2007530690A (ja) 2004-03-29 2007-11-01 メルク　エンド　カムパニー　インコーポレーテッド １１−β−ヒドロキシステロイドデヒドロゲナーゼ−１の阻害剤としてのジアリールトリアゾール
TW200602335A (en) 2004-03-31 2006-01-16 Kissei Pharmaceutical Naphthalene derivative, medicinal composition containing the same, and medicinal use thereof
EP1731524A4 (en) 2004-03-31 2009-05-20 Kissei Pharmaceutical PHENOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE DERIVATIVE, AND ITS MEDICINAL USE
WO2005095372A1 (ja) 2004-03-31 2005-10-13 Kissei Pharmaceutical Co., Ltd. ナフタレン誘導体、それを含有する医薬組成物及びその医薬用途
JP2007530631A (ja) 2004-04-02 2007-11-01 ノバルティス アクチエンゲゼルシャフト チアゾロピリジン誘導体、それを含む医薬組成物およびグルコキナーゼ介在性状態の処置法
EP1735322B1 (en) 2004-04-02 2011-09-14 Novartis AG Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful for the treatment of type 2 diabetes
JP2007261945A (ja) 2004-04-07 2007-10-11 Taisho Pharmaceut Co Ltd チアゾール誘導体
JP2007531780A (ja) 2004-04-10 2007-11-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規な２−アミノ−イミダゾ［４，５−ｄ］ピリダジン−４−オン及び２−アミノ−イミダゾ［４，５−ｃ］ピリダジン−４−オン、その製法及び医薬としての使用
US7179809B2 (en) 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
EP1735275B1 (en) 2004-04-14 2010-08-18 Amgen Inc. Aryl sulfones and uses related thereto
GB0408771D0 (en) 2004-04-20 2004-05-26 Sterix Ltd Compound
WO2005118538A2 (en) 2004-04-20 2005-12-15 Amgen, Inc. Arylsulfonamides and uses as hydroxysteroid dehydrogenase
US20080242869A1 (en) 2004-04-21 2008-10-02 Matthew Fyfe Tri(Cyclo) Substituted Amide Compounds
US20050239778A1 (en) 2004-04-22 2005-10-27 Boehringer Ingelheim International Gmbh Novel medicament combinations for the treatment of respiratory diseases
US20050244502A1 (en) 2004-04-28 2005-11-03 Mathias Neil R Composition for enhancing absorption of a drug and method
US20050245533A1 (en) 2004-04-29 2005-11-03 Hoff Ethan D Inhibitors of the 11-beta-hydroxysteroid dehydrogenaseType 1 enzyme and their therapeutic application
US20050245534A1 (en) 2004-04-29 2005-11-03 Link James T Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US20050245532A1 (en) 2004-04-29 2005-11-03 Hoff Ethan D Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application
US7880001B2 (en) 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US20050261302A1 (en) 2004-04-29 2005-11-24 Hoff Ethan D Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application
WO2005107730A2 (en) * 2004-05-03 2005-11-17 Omega Bio-Pharma (I.P.3) Limited Cysteamines for treating complications of hypercholesterolemia and diabetes
CA2565843A1 (en) 2004-05-06 2005-11-17 Pfizer Inc. Novel compounds of proline and morpholine derivatives
NZ551077A (en) 2004-05-07 2009-05-31 Janssen Pharmaceutica Nv Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
NZ551076A (en) 2004-05-07 2009-05-31 Janssen Pharmaceutica Nv Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
US7439370B2 (en) 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
AU2005247684B2 (en) 2004-05-12 2008-10-23 Pfizer Products Inc. Proline derivatives and their use as dipeptidyl peptidase IV inhibitors
DE102004024454A1 (de) 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
PE20060315A1 (es) 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
BRPI0510394A (pt) 2004-05-24 2007-11-13 Amgen Inc inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1
TWI354569B (en) 2004-05-28 2011-12-21 Bristol Myers Squibb Co Coated tablet formulation and method
ZA200610041B (en) 2004-06-01 2008-07-30 Ares Trading Sa Method of stabilizing proteins
CA2569095A1 (en) 2004-06-03 2005-12-15 Pfizer Products Inc. Crystal structure of dipeptidyl peptidase iv (dpp-iv) and uses thereof
US7935723B2 (en) 2004-06-04 2011-05-03 Novartis Pharma Ag Use of organic compounds
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
EP1604989A1 (en) 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft DPP-IV inhibitors
EP1753459A2 (en) 2004-06-09 2007-02-21 Yasoo Health Composition and method for improving pancreatic islet cell survival
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
US8071624B2 (en) 2004-06-24 2011-12-06 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
US20050288317A1 (en) 2004-06-24 2005-12-29 Wenqing Yao Amido compounds and their use as pharmaceuticals
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
EA200700118A1 (ru) 2004-06-24 2007-08-31 Инсайт Корпорейшн Амидосоединения и их применение в качестве лекарственных средств
JP2008504276A (ja) 2004-06-24 2008-02-14 インサイト・コーポレイション アミド化合物およびその医薬としての使用
EP1773773A4 (en) 2004-06-24 2009-07-29 Incyte Corp AMID COMPOUNDS AND THEIR USE AS MEDICAMENTS
EP1763517B1 (en) 2004-06-28 2011-05-11 F. Hoffmann-La Roche AG Pyrimidine derivatives as 11beta-hsd1 inhibitors
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
CA2511269A1 (en) * 2004-07-07 2006-01-07 F. Hoffmann-La Roche Ag Multimarker panel based on p1gf for diabetes type 1 and 2
CN101018550A (zh) 2004-07-14 2007-08-15 诺瓦提斯公司 Dpp－iv抑制剂与调节5－ht3和/或5－ht4受体的化合物的组合
DE102004034690A1 (de) 2004-07-17 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
JP2008508213A (ja) 2004-07-27 2008-03-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄ−グルコピラノシル−フェニル置換環状体、そのような化合物を含有する医薬品、それらの使用及びその製造方法
SI1789041T1 (sl) 2004-07-28 2008-10-31 Hoffmann La Roche Derivati aril-piridina kot inhibitorji 11-beta-hsd1
US20060025445A1 (en) 2004-08-02 2006-02-02 Xiang Jason S 11-Beta HSD1 inhibitors
JP2008509146A (ja) 2004-08-06 2008-03-27 メルク エンド カムパニー インコーポレーテッド １１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ−１の阻害剤としてのスルホニル化合物
JP2006045156A (ja) 2004-08-06 2006-02-16 Sumitomo Pharmaceut Co Ltd 縮合ピラゾール誘導体
CN101080226A (zh) 2004-08-10 2007-11-28 因塞特公司 酰氨基化合物及它们作为药物的用途
WO2006018150A1 (de) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
GB0418046D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
GB0418058D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Fluorination process
MX2007001650A (es) 2004-08-12 2007-07-13 Prosidion Ltd Fenilacetamidas substituidas y su uso como activadores de glucocinasa.
TW200613275A (en) 2004-08-24 2006-05-01 Recordati Ireland Ltd Lercanidipine salts
EP1782832A4 (en) 2004-08-26 2009-08-26 Takeda Pharmaceutical MEANS FOR THE TREATMENT OF DIABETES
CA2576839C (en) 2004-08-30 2013-07-02 Janssen Pharmaceutica N.V. N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
ATE445600T1 (de) 2004-08-30 2009-10-15 Janssen Pharmaceutica Nv Derivate von tricyclischem lactam als 11-beta- hydroxysteroid-dehydrogenase-inhibitoren
DE102004043944A1 (de) 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CN101014578B (zh) 2004-09-16 2011-01-19 安斯泰来制药有限公司 三唑衍生物或其盐
JP4671648B2 (ja) 2004-09-17 2011-04-20 株式会社ソニー・コンピュータエンタテインメント 中継器、エンタテインメント装置、通信システム、通信方法、及びプログラム
CN1759834B (zh) 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
CA2580461A1 (en) 2004-09-23 2006-04-06 Amgen Inc. Substituted sulfonamidopropionamides and methods of use
MX2007003785A (es) 2004-09-29 2007-07-12 Kissei Pharmaceutical Compuesto heterociclico nitrogenoso 1-(b-d-glicopiranosil)-3, composicion medicinal que contiene el mismo, y uso medicinal del mismo.
DE102004048388A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
RU2383533C2 (ru) 2004-10-04 2010-03-10 Ф.Хоффманн-Ля Рош Аг Алкилированные производные пиридина в качестве ингибиторов 11-бета при диабете
MX2007004021A (es) 2004-10-08 2007-05-24 Novartis Ag Combinacion de compuestos organicos.
JP4959569B2 (ja) 2004-10-12 2012-06-27 グレンマーク・ファーマシューティカルズ・エスエー 新規なジペプチジルペプチダーゼｉｖ阻害剤、それらを含む医薬品組成物、およびそれらを調製するためのプロセス
WO2006040329A1 (en) 2004-10-12 2006-04-20 Novo Nordisk A/S 1 ibeta- hydroxysteroid dehydrogenase type 1 active spiro compounds
GB0423044D0 (en) 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
GB0423043D0 (en) 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
RU2007119320A (ru) 2004-10-25 2008-11-27 Новартис АГ (CH) Комбинация ингибитора dpp-iv, антидиабетического агента ppar и метформина
ATE419848T1 (de) 2004-10-29 2009-01-15 Lilly Co Eli Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
EP1812407A2 (en) 2004-11-02 2007-08-01 Pfizer, Inc. Novel compounds of substituted and unsubstituted adamantyl amides
AU2005301608B2 (en) 2004-11-02 2012-09-13 Msd K.K. Aryloxy-substituted benzimidazole derivatives
DE102005013967A1 (de) 2004-11-05 2006-10-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Bradykinin-B1-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1655283A1 (en) 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
EP1666467A1 (en) 2004-11-08 2006-06-07 Evotec AG 11Beta-HSD1 Inhibitors
EP1659113A1 (en) 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
WO2006051662A1 (ja) 2004-11-09 2006-05-18 Taisho Pharmaceutical Co., Ltd. チアゾール誘導体
BRPI0517567A (pt) 2004-11-09 2008-06-17 Smithkline Beecham Corp composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo, composição farmacêutica, usos de um composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo e de uma composição farmacêutica, e, processo para preparar um composto
JP2006137678A (ja) 2004-11-10 2006-06-01 Shionogi & Co Ltd インターロイキン−２組成物
MX2007005527A (es) 2004-11-10 2007-07-09 Incyte Corp Compuestos de lactama y sus usos como farmaceuticos.
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055435A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
US7214704B2 (en) 2004-11-15 2007-05-08 Bristol-Myers Squibb Company 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055462A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7750145B2 (en) 2004-11-18 2010-07-06 Kissei Pharmaceutical Co., Ltd. 1-substituted-3-β-D-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same
EP1824842A4 (en) 2004-11-18 2009-08-26 Incyte Corp INHIBITORS OF 11-HYDROXYL STEROID DEHYDROGENASE TYPE 1 AND METHOD OF USE
GB0425919D0 (en) 2004-11-25 2004-12-29 Prosidion Ltd Indole-2-carboxylic acid amides
WO2006059163A1 (en) 2004-12-02 2006-06-08 Prosidion Limited Treatment of diabetes with glycogen phosphorylase inhibitors
WO2006059165A1 (en) 2004-12-02 2006-06-08 Prosidion Limited Pyrrolopyridine-2-carboxylic acid amide derivative useful as inhibitor of glycogen phosphorylase
JP2008521873A (ja) 2004-12-02 2008-06-26 プロシディオン・リミテッド ピロロピリジン−２−カルボン酸アミド類
MX2007006420A (es) 2004-12-03 2007-07-19 Novo Nordisk As Activadores heteroaromaticos de glucocinasa.
JP2008007405A (ja) 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
US7687469B2 (en) 2004-12-16 2010-03-30 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
JP2008524244A (ja) 2004-12-17 2008-07-10 タケダ サン ディエゴ インコーポレイテッド 水酸化ステロイド脱水素酵素阻害剤
DK1830841T3 (da) 2004-12-20 2008-10-13 Lilly Co Eli Cycloalkyllactamderivater som inhibitorer af 11-beta-hydroxysteroid-dehydrogenase 1
WO2006068991A1 (en) 2004-12-21 2006-06-29 Eli Lilly And Company Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2006068199A1 (ja) 2004-12-22 2006-06-29 Mochida Pharmaceutical Co., Ltd. 代謝的に安定な３－オキシ－１，２，４－トリアゾール誘導体
AU2005320134B2 (en) 2004-12-24 2011-04-28 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic pyrrole derivatives
KR100760430B1 (ko) 2004-12-31 2007-10-04 한미약품 주식회사 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
WO2006074244A2 (en) 2005-01-05 2006-07-13 Abbott Laboratories Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US20060148871A1 (en) 2005-01-05 2006-07-06 Rohde Jeffrey J Metabolic stabilization of substituted adamantane
JP5133702B2 (ja) 2005-01-05 2013-01-30 アボット・ラボラトリーズ １１−β−ヒドロキシステロイドデヒドロゲナーゼ１型酵素の阻害薬
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
GT200600008A (es) 2005-01-18 2006-08-09 Formulacion de compresion directa y proceso
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
WO2006080533A1 (ja) 2005-01-31 2006-08-03 Mochida Pharmaceutical Co., Ltd. ３－アミノ－１,２,４－トリアゾール誘導体
AR053329A1 (es) 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
EP1848693A1 (en) 2005-02-05 2007-10-31 AstraZeneca AB Indan-amide derivatives with glycogen phosphorylase inhibitory activity
US20100137397A1 (en) 2005-02-05 2010-06-03 Astrazeneca Ab Chemical Compounds
JP5020065B2 (ja) 2005-02-15 2012-09-05 キッセイ薬品工業株式会社 １−置換−７−（β−Ｄ−グリコピラノシルオキシ）（アザ）インドール化合物、及びそれを含有する医薬
CA2598610C (en) 2005-03-03 2011-05-31 F. Hoffmann-La Roche Ag 1-sulfonyl-piperidine-3-carboxylic acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus
WO2006095822A1 (ja) 2005-03-11 2006-09-14 Ono Pharmaceutical Co., Ltd. スルホンアミド化合物およびその医薬
EP1868685A2 (en) 2005-03-18 2007-12-26 onepharm GmbH 11ß-HYDROXYSTEROID DEHYDROGENASES
GB0506133D0 (en) 2005-03-24 2005-05-04 Sterix Ltd Compound
JPWO2006104280A1 (ja) 2005-03-31 2008-09-11 武田薬品工業株式会社 糖尿病の予防・治療剤
JP5140577B2 (ja) 2005-03-31 2013-02-06 タケダ カリフォルニア インコーポレイテッド ヒドロキシステロイドデヒドロゲナーゼ阻害剤
BRPI0610459A2 (pt) 2005-04-05 2010-06-22 Hoffmann La Roche composto, processo para a sua preparação, composições farmacêuticas que o compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de deidrogenase de hidroxiesteróides-11b e utilização do composto
WO2006106423A2 (en) 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
US20060235028A1 (en) 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
ES2338041T3 (es) 2005-04-15 2010-05-03 Boehringer Ingelheim International Gmbh Derivados de (heteroariloxi-bencil)-benceno sustituidos con glucopiranosilo en calidad de inhibidores de sglt.
EP1873144B1 (en) 2005-04-20 2014-07-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
WO2006111169A1 (en) 2005-04-21 2006-10-26 Gastrotech Pharma A/S Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
AP2007004234A0 (en) 2005-04-22 2007-12-31 Alantos Pharm Holding Dipeptidyl peptidase-IV inhibitors
JP4749417B2 (ja) 2005-04-25 2011-08-17 株式会社日立製作所 磁気共鳴を用いた検査装置および核磁気共鳴信号受信用コイル
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
AU2006250354A1 (en) 2005-05-23 2006-11-30 Japan Tobacco Inc. Pyrazole compound and therapeutic agent for diabetes comprising the same
JP2008542247A (ja) 2005-05-24 2008-11-27 アストラゼネカ アクチボラグ グルコキナーゼモジュレーターとしての２−フェニル置換イミダゾール［４，５ｂ］ピリジン／ピラジンおよびプリン誘導体
RU2007143161A (ru) 2005-05-25 2009-07-10 Вайет (Us) Способы синтеза замещенных 3-цианохинов и их продуктов
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
CN101237870B (zh) 2005-06-03 2011-05-25 田边三菱制药株式会社 伴随的药物试剂及其用途
US8952176B2 (en) 2005-06-07 2015-02-10 Shionogi & Co., Ltd. Heterocyclic compound having type I 11 β hydroxysteroid dehydrogenase inhibitory activity
WO2006132436A1 (ja) 2005-06-08 2006-12-14 Japan Tobacco Inc. 複素環化合物
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
GT200600218A (es) 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
WO2006134481A1 (en) 2005-06-16 2006-12-21 Pfizer Inc. Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1
EP1893609B1 (en) 2005-06-16 2009-11-18 Pfizer, Inc. N-(pyridin-2-yl)-sulfonamide derivatives
US7605289B2 (en) 2005-06-17 2009-10-20 Amgen, Inc. Benzamide derivatives and uses related thereto
US7585630B2 (en) 2005-06-20 2009-09-08 Decode Genetics Ehf. Genetic variants in the TCF7L2 gene as diagnostic markers for risk of type 2 diabetes mellitus
CN101212966B (zh) 2005-07-01 2012-03-14 默沙东公司 合成cetp抑制剂的方法
NZ564260A (en) 2005-07-05 2010-12-24 Hoffmann La Roche Pyridazine derivatives as 11beta-hydroxysteroid dehydrogenase type 1 inhibitors
PE20070374A1 (es) 2005-07-08 2007-05-12 Pfizer Ltd ANTICUERPOS ANTI-MAdCAM
US7999114B2 (en) 2005-07-08 2011-08-16 Novo Nordisk A/S Dicycloalkylcarbamoyl ureas as glucokinase activators
WO2007007688A1 (ja) 2005-07-08 2007-01-18 Mochida Pharmaceutical Co., Ltd. ３,５－ジアミノ－１,２,４－トリアゾール誘導体
MX2008000294A (es) 2005-07-08 2008-04-04 Novo Nordisk As Activadores de dicicloalquil urea glucocinasa.
EP2305674A1 (en) 2005-07-09 2011-04-06 AstraZeneca AB Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
EP2027113A1 (en) 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
EP1910350A1 (en) 2005-07-09 2008-04-16 AstraZeneca AB 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
BRPI0613451A2 (pt) 2005-07-11 2011-01-11 Mitsubishi Tanabe Pharma Corp ativador de glicocinase, derivado de oxima, método para a preparação do referido derivado de oxima e uso
EP1905769B1 (en) 2005-07-13 2017-03-29 Msd K.K. Heterocycle-substituted benzimidazole derivative
BRPI0612996A2 (pt) 2005-07-14 2010-12-14 Novo Nordisk As ativadores de urÉia glucocinase
JP2009505955A (ja) 2005-07-22 2009-02-12 アムゲン インコーポレイティッド アニリンスルホンアミド誘導体およびそれらの使用
UY29694A1 (es) 2005-07-28 2007-02-28 Boehringer Ingelheim Int Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20100160286A1 (en) 2005-08-09 2010-06-24 Astrazeneca Uk Limited Ab Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
AU2006278039B2 (en) 2005-08-11 2010-10-21 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising a DPP-lV inhibitor
US7622492B2 (en) 2005-08-31 2009-11-24 Hoffmann-La Roche Inc. Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase
EP1760076A1 (en) 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
CA2622472C (en) 2005-09-14 2013-11-19 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
GEP20135791B (en) 2005-09-14 2013-03-25 Takeda Pharmaceutical Use of dipeptidyl peptidase inhibitors
BRPI0616245A2 (pt) 2005-09-16 2011-06-14 Arena Pharm Inc modulador de metabolismo, seus usos, composiÇço farmaceutica compreendendo o mesmo, bem como mÉtodo para produÇço da referida composiÇço
ATE514435T1 (de) 2005-09-20 2011-07-15 Novartis Pharma Gmbh Verwendung eines dpp-iv-hemmers zur minderung hypoglykämischer ereignisse
WO2007038979A1 (en) 2005-09-22 2007-04-12 Swissco Development Ag Effervescent metformin composition and tablets and granules made therefrom
JOP20180109A1 (ar) 2005-09-29 2019-01-30 Novartis Ag تركيبة جديدة
BRPI0616640A2 (pt) 2005-09-30 2011-06-28 Novartis Ag combinação de compostos orgánicos
WO2007050485A2 (en) 2005-10-25 2007-05-03 Merck & Co., Inc. Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension
JP2009515005A (ja) 2005-11-04 2009-04-09 エルエス ケーブル リミテッド 水酸化マグネシウムポリマーハイブリッド粒子の製造方法
CA2633167A1 (en) 2005-12-16 2007-07-12 Merck & Co., Inc. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
RU2008129873A (ru) 2005-12-23 2010-01-27 Новартис АГ (CH) Конденсированные гетероциклические соединения, полезные в качестве ингибиторов дпп-iv
WO2007120936A2 (en) 2006-01-06 2007-10-25 Novartis Ag Use.of vildagliptin for the treatment of diabetes
TW200801029A (en) 2006-02-15 2008-01-01 Boehringer Ingelheim Int Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
WO2007099345A1 (en) 2006-03-02 2007-09-07 Betagenon Ab Medical use of bmp-2 and/ or bmp-4
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
US8455435B2 (en) 2006-04-19 2013-06-04 Ludwig-Maximilians-Universitat Munchen Remedies for ischemia
CA2810522A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Polymorphs
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
KR20070111099A (ko) 2006-05-16 2007-11-21 영진약품공업주식회사 시타글립틴 염산염의 신규 결정형, 이의 제조 방법과 이를포함하는 약학적 조성물
EP2020996B1 (en) 2006-05-16 2011-11-23 Gilead Sciences, Inc. Method and compositions for treating hematological malignancies
WO2007137107A2 (en) 2006-05-19 2007-11-29 Abbott Laboratories Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
KR100858848B1 (ko) 2006-05-23 2008-09-17 한올제약주식회사 메트포르민 서방정
WO2007149797A2 (en) 2006-06-19 2007-12-27 Novartis Ag Use of organic compounds
WO2007148185A2 (en) 2006-06-21 2007-12-27 Pfizer Products Inc. Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
AT503443B1 (de) 2006-06-23 2007-10-15 Leopold Franzens Uni Innsbruck Verfahren zur herstellung einer eisfläche für eissportbahnen
TW200811147A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
TW200811140A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
JP2010500326A (ja) 2006-08-08 2010-01-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病の治療のためのｄｐｐ−ｉｖ阻害剤としてのピロロ［３，２−ｄ］ピリミジン
WO2008020011A1 (en) 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
AU2007285827A1 (en) 2006-08-17 2008-02-21 Wellstat Therapeutics Corporation Combination treatment for metabolic disorders
DE102006042586B4 (de) 2006-09-11 2014-01-16 Betanie B.V. International Trading Verfahren zum mikropartikulären Beladen von hochpolymeren Kohlenhydraten mit hydrophoben Wirkflüssigkeiten
JP2010508371A (ja) 2006-11-06 2010-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換フェニル誘導体、該化合物を含有する医薬品及びその使用と製造方法
US7956201B2 (en) 2006-11-06 2011-06-07 Hoffman-La Roche Inc. Process for the preparation of (S)-4-fluoromethyl-dihydro-furan-2-one
MY157828A (en) 2006-11-09 2016-07-29 Boehringer Ingelheim Int Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
US8101634B2 (en) 2006-12-06 2012-01-24 Glaxosmithkline Llc Bicyclic compounds and use as antidiabetics
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
AR064736A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr
CL2008000133A1 (es) 2007-01-19 2008-05-23 Boehringer Ingelheim Int Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido combinado con al menos un segundo agente terapeutico; y uso de la composicion para el tratamiento de diabetes mellitus, cataratas, neuropatia, infarto de miocardio, e
CA2677201C (en) 2007-02-01 2015-11-17 Takeda Pharmaceutical Company Limited Solid preparation comprising alogliptin and pioglitazone
TW200836774A (en) 2007-02-01 2008-09-16 Takeda Pharmaceutical Solid preparation
CA2677457A1 (en) 2007-02-06 2008-08-14 Helen Tuvesson Andersson New compounds, methods for their preparation and use thereof
JP2010521492A (ja) 2007-03-15 2010-06-24 ネクティド，インク． 徐放性ビグアニド組成物、および即時性ジペプチジルペプチダーゼｉｖ阻害剤組成物を含む抗糖尿病合剤
CN103330939A (zh) 2007-04-03 2013-10-02 田边三菱制药株式会社 二肽基肽酶iv抑制化合物和甜味剂的并用
EP2142113B1 (en) 2007-04-16 2023-01-11 Smith & Nephew, Inc. Powered surgical system
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
JP2010526145A (ja) 2007-05-04 2010-07-29 ブリストル−マイヤーズ スクイブ カンパニー ［６，６］および［６，７］−二環式ｇｐｒ１１９ｇタンパク質結合受容体アゴニスト
BRPI0721862B1 (pt) 2007-07-09 2016-03-15 Symrise Ag preparação compreendendo sais solúveis estáveis de ácido fenilbenzimidazol sulfônico, e uso de aminoácidos básicos
KR101536786B1 (ko) 2007-07-19 2015-07-14 다케다 야쿠힌 고교 가부시키가이샤 알로그립틴 및 메트포르민 히드로클로라이드를 포함하는 고체 제제
PE20090597A1 (es) 2007-08-16 2009-06-06 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
PE20090603A1 (es) 2007-08-16 2009-06-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv
CL2008002424A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido; y uso de la composicion farmaceutica para el tratamiento de la diabetes mellitus, tolerancia anormal a la glucosa e hiperglucemia, trastornos metabolicos, entre otras.
NZ600126A (en) 2007-08-17 2013-12-20 Boehringer Ingelheim Int Purine derivatives for use in the treatment of fap-related diseases
US8338450B2 (en) 2007-09-21 2012-12-25 Lupin Limited Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors
CN104072613A (zh) 2007-11-13 2014-10-01 Evec股份有限公司 与hGM-CSF结合的单克隆抗体及包含它的药物组合物
CN101861333A (zh) 2007-11-16 2010-10-13 诺沃-诺迪斯克有限公司 包含glp-1肽或毒蜥外泌肽-4和基础胰岛素肽的药物组合物
CN101234105A (zh) 2008-01-09 2008-08-06 北京润德康医药技术有限公司 一种含有二甲双胍和维格列汀的药用组合物及其制备方法
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
US20090186086A1 (en) 2008-01-17 2009-07-23 Par Pharmaceutical, Inc. Solid multilayer oral dosage forms
TW200936136A (en) 2008-01-28 2009-09-01 Sanofi Aventis Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application
CN101932241A (zh) 2008-02-05 2010-12-29 默沙东公司 二甲双胍和二肽基肽酶-ⅳ抑制剂的组合的药物组合物
EP2259676A4 (en) 2008-03-04 2011-03-16 Merck Sharp & Dohme PHARMACEUTICAL COMPOSITIONS OF A COMBINATION OF METFORMIN AND A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
AU2009220615B2 (en) 2008-03-05 2013-12-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
US8551524B2 (en) 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
US20090270404A1 (en) 2008-03-31 2009-10-29 Metabolex, Inc. Oxymethylene aryl compounds and uses thereof
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
CN101590007A (zh) 2008-05-27 2009-12-02 北京瑞伊人科技发展有限公司 一种盐酸二甲双胍/伏格列波糖降糖口服制剂组合物及其制备
PE20100156A1 (es) 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
MX2011001525A (es) 2008-08-15 2011-03-29 Boehringer Ingelheim Int Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
JP2010053576A (ja) 2008-08-27 2010-03-11 Sumitomo Forestry Co Ltd 舗装用マット
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
UY32177A (es) 2008-10-16 2010-05-31 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
WO2010045656A2 (en) 2008-10-17 2010-04-22 Nectid, Inc. Novel sglt2 inhibitor dosage forms
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
TWI466672B (zh) 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
DK2395983T3 (da) 2009-02-13 2020-07-13 Boehringer Ingelheim Int Farmaceutisk sammensætning omfattende en sglt2-inhibitor, en dpp-iv-inhibitor og eventuelt et yderligere antidiabetisk middel og anvendelser deraf
EA029759B1 (ru) 2009-02-13 2018-05-31 Бёрингер Ингельхайм Интернациональ Гмбх Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
UY32427A (es) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
TW201031661A (en) 2009-02-17 2010-09-01 Targacept Inc Fused benzazepines as neuronal nicotinic acetylcholine receptor ligands
US20120095028A1 (en) 2009-03-20 2012-04-19 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
BRPI1013992A2 (pt) 2009-04-27 2016-08-16 Revalesio Corp composições e métodos para o tratamento de resistência à insulina e diabetes melito
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
WO2010140111A1 (en) 2009-06-02 2010-12-09 Ranbaxy Laboratories Limited Pharmaceutical compositions containing a combination of an antihistamine and a decongestant
AU2010260373A1 (en) 2009-06-15 2012-01-12 Merck Sharp & Dohme Corp. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
CN108938585A (zh) 2009-07-21 2018-12-07 凯克斯生物制药公司 柠檬酸铁剂型
NZ598170A (en) 2009-10-02 2014-06-27 Boehringer Ingelheim Int Pharmaceutical compositions comprising bi-1356 and metformin
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
JP5446716B2 (ja) 2009-10-21 2014-03-19 大正製薬株式会社 アルギニン及びカルニチン含有錠剤の製造方法
ES2760917T3 (es) 2009-11-27 2020-05-18 Boehringer Ingelheim Int Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina
JP2010070576A (ja) 2009-12-28 2010-04-02 Sato Pharmaceutical Co Ltd 速溶解性錠剤
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
KR20130069615A (ko) 2010-05-05 2013-06-26 베링거 인겔하임 인터내셔날 게엠베하 피오글리타존 및 리나글립틴을 포함하는 약제학적 제형
JP6034781B2 (ja) 2010-05-05 2016-11-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 併用療法
JP5707489B2 (ja) 2010-06-09 2015-04-30 ポクセル・エスアーエスＰｏｘｅｌｓａｓ １型糖尿病の処置
AU2011271124A1 (en) 2010-06-22 2013-01-10 Twi Pharmaceuticals, Inc. Controlled release compositions with reduced food effect
CA3164653A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh A combination comprising linagliptin and a long-acting insulin
US20130224296A1 (en) 2010-09-03 2013-08-29 Bristol-Myers Squibb Company Drug Formulations Using Water Soluble Antioxidants
WO2012039420A1 (ja) 2010-09-21 2012-03-29 国立大学法人九州大学 動脈圧反射機能障害に関連した疾患を治療するためのバイオニック動脈圧反射システム
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2012088682A1 (en) 2010-12-29 2012-07-05 Shanghai Fochon Pharmaceutical Co Ltd. 2-(3-aminopiperidin-1-yl)-[1,2,4]triazolo[1,5-c]pyrimidine-5,7(3h,6h)-dione derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
AU2012212448B9 (en) 2011-02-01 2015-06-25 Astrazeneca Uk Limited Pharmaceutical formulations including an amine compound
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
WO2012152837A1 (en) 2011-05-10 2012-11-15 Sandoz Ag Polymorph of linagliptin benzoate
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
CN106968050B (zh) 2012-01-04 2019-08-27 宝洁公司 具有多个区域的含活性物质纤维结构
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
EP2854812A1 (en) 2012-05-24 2015-04-08 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2013174769A1 (en) 2012-05-25 2013-11-28 Boehringer Ingelheim International Gmbh Use of keratinocytes as a biologically active substance in the treatment of wounds, such as diabetic wounds, optionally in combination with a dpp-4 inhibitor
WO2013179307A2 (en) 2012-05-29 2013-12-05 Mylan Laboratories Limited Stabilized pharmaceutical compositions of saxagliptin
NZ704604A (en) 2012-08-24 2018-06-29 Novartis Ag Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling
EP2908806A1 (en) 2012-10-09 2015-08-26 Boehringer Ingelheim International GmbH Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets
US20140100292A1 (en) 2012-10-09 2014-04-10 Boehringer Ingelheim International Gmbh Use of moisture-conditioned disintegrants or expanding agents in tablet manufacture for the selective adjustment of the mechanical properties, the dissolving kinetics and/or the water loading of the tablets
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
CA2903577C (en) 2013-03-15 2023-10-17 Boehringer Ingelheim International Gmbh Use of linagliptin in cardio- and renoprotective antidiabetic therapy
AU2014255727B2 (en) 2013-04-18 2019-07-25 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2014184376A1 (en) 2013-05-17 2014-11-20 Boehringer Ingelheim International Gmbh Combination of a dpp-4 inhibitor and an alpha-glucosidase inhibitor
CN105283187A (zh) 2013-06-14 2016-01-27 勃林格殷格翰国际有限公司 用于治疗糖尿病及其并发症的二肽基肽酶-4抑制剂
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
CN104130258B (zh) 2014-08-13 2016-06-01 广东东阳光药业有限公司 一种二聚体的转化方法
US20160106677A1 (en) 2014-10-17 2016-04-21 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ
WO2020016232A1 (en) 2018-07-17 2020-01-23 Boehringer Ingelheim International Gmbh Cardiosafe antidiabetic therapy

Also Published As

Publication number Publication date
MX2020009911A (es) 2020-10-14
HK1204548A1 (en) 2015-11-27
KR20170136018A (ko) 2017-12-08
WO2007128761A3 (de) 2008-03-06
JP6662970B2 (ja) 2020-03-11
JP2022027926A (ja) 2022-02-14
MY172012A (en) 2019-11-12
US9173859B2 (en) 2015-11-03
CA2897719A1 (en) 2007-11-15
JP2013199503A (ja) 2013-10-03
EP2397142B1 (de) 2022-07-27
JP2017105849A (ja) 2017-06-15
CN102846619A (zh) 2013-01-02
JP2015180686A (ja) 2015-10-15
CN110251519A (zh) 2019-09-20
KR20200128209A (ko) 2020-11-11
NZ572863A (en) 2012-01-12
SI2015754T1 (sl) 2014-05-30
KR101558938B1 (ko) 2015-10-08
US20110065731A1 (en) 2011-03-17
KR20090021152A (ko) 2009-02-27
NZ609765A (en) 2014-12-24
CA2651019C (en) 2015-09-22
PH12013501790A1 (en) 2014-09-22
KR20150082668A (ko) 2015-07-15
CN102125560A (zh) 2011-07-20
EP2015754A2 (de) 2009-01-21
JP2010159305A (ja) 2010-07-22
CA2897719C (en) 2019-06-18
JP5813293B2 (ja) 2015-11-17
EP2397142A2 (de) 2011-12-21
CN104095854A (zh) 2014-10-15
IL195031A0 (en) 2009-08-03
EA036523B1 (ru) 2020-11-19
EP4104838A1 (de) 2022-12-21
PL2015754T3 (pl) 2014-08-29
TWI500423B (zh) 2015-09-21
EP2407168A1 (de) 2012-01-18
US20170087160A1 (en) 2017-03-30
NO345061B1 (no) 2020-09-14
EP2351568A2 (de) 2011-08-03
SG171648A1 (en) 2011-06-29
DK2015754T3 (da) 2014-06-10
JP6995822B2 (ja) 2022-02-21
US10080754B2 (en) 2018-09-25
TWI524894B (zh) 2016-03-11
CA2875706C (en) 2016-07-26
KR20220140016A (ko) 2022-10-17
MX358618B (es) 2018-08-29
AU2007247141A1 (en) 2007-11-15
US20200222411A1 (en) 2020-07-16
AR060757A1 (es) 2008-07-10
US8232281B2 (en) 2012-07-31
CA2875706A1 (en) 2007-11-15
PH12013501791A1 (en) 2014-09-22
MY174080A (en) 2020-03-09
EA202091999A2 (ru) 2021-01-29
CY1115350T1 (el) 2017-01-04
KR101655754B1 (ko) 2016-09-08
KR20160107361A (ko) 2016-09-13
AU2007247141B2 (en) 2013-09-12
ES2928734T3 (es) 2022-11-22
JP5927146B2 (ja) 2016-05-25
EP2397142A3 (en) 2012-03-28
US20070281940A1 (en) 2007-12-06
TW200808323A (en) 2008-02-16
US20160000798A1 (en) 2016-01-07
EA200802204A1 (ru) 2009-04-28
EP2015754B1 (de) 2014-04-09
NO20084341L (no) 2008-12-02
JP2013199504A (ja) 2013-10-03
CL2012002527A1 (es) 2012-12-21
PE20110235A1 (es) 2011-04-14
TW201433316A (zh) 2014-09-01
ME01787B (me) 2014-09-20
ZA200808282B (en) 2009-08-26
JP2013213064A (ja) 2013-10-17
KR20140048344A (ko) 2014-04-23
CN107252430A (zh) 2017-10-17
CA2833705A1 (en) 2007-11-15
JP2020063293A (ja) 2020-04-23
US20180353513A1 (en) 2018-12-13
JP5734564B2 (ja) 2015-06-17
EA201300213A1 (ru) 2013-06-28
JP2018193408A (ja) 2018-12-06
JP6143809B2 (ja) 2017-06-07
JP2024028665A (ja) 2024-03-04
MY174380A (en) 2020-04-14
CN101460173A (zh) 2009-06-17
MX2008014025A (es) 2008-11-14
US20140135348A1 (en) 2014-05-15
KR101806786B1 (ko) 2017-12-08
CA2651019A1 (en) 2007-11-15
ECSP088866A (es) 2008-12-30
KR20190015625A (ko) 2019-02-13
CL2012002528A1 (es) 2012-12-21
RS53272B (en) 2014-08-29
PT2015754E (pt) 2014-04-23
UA102669C2 (en) 2013-08-12
US8673927B2 (en) 2014-03-18
EP2351568A3 (de) 2011-11-23
EA036618B1 (ru) 2020-11-30
PE20080251A1 (es) 2008-04-25
KR20140048345A (ko) 2014-04-23
PH12013501791B1 (en) 2014-09-22
CN108635355A (zh) 2018-10-12
CL2012002526A1 (es) 2012-12-21
HRP20140645T1 (hr) 2014-09-26
US20220184088A1 (en) 2022-06-16
EA202091999A3 (ru) 2021-11-30
CA2833705C (en) 2017-03-07
CN110227078A (zh) 2019-09-13
WO2007128761A2 (de) 2007-11-15
ES2474866T3 (es) 2014-07-09
PH12013501790B1 (en) 2014-09-22
BRPI0711308A2 (pt) 2011-12-06
JP2009535381A (ja) 2009-10-01
JP2013199505A (ja) 2013-10-03
UY30321A1 (es) 2008-01-02
US11291668B2 (en) 2022-04-05

Similar Documents

Publication Publication Date Title
PT2397142T (pt) Utilizações de inibidores da dpp iv
HK1225722A1 (zh) 激酶活性抑製劑
EP2026843A4 (en) THERAPEUTIC USES OF RTP801L INHIBITORS
HRP20150003T1 (en) Dpp iv inhibitor formulations
HK1119696A1 (en) Pyridopyrimidinone inhibitors of pi3k pi3k
IL199727A0 (en) Inhibitors of mek
GB0621607D0 (en) Inhibitors of c-Met
EP2192838A4 (en) HETEROCYCLIC NEKROPTOSIS HEMMER
IL211835A0 (en) Therapeutic uses of inhibitors of rtp801
IL201367A0 (en) 2 - morpholin - 4 - yl - pyrimidines as pi3k inhibitors
GB0622084D0 (en) Inhibitors of HSP90
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
EP2142188A4 (en) PROCESS FOR SUPPRESSING LTP INHIBITION
GB0608822D0 (en) Inhibitors of DHFR
IL195722A0 (en) Therapeutic uses of inhibitors of rtp801l
GB0625381D0 (en) Novel inhibitors of flaviridae
GB0621107D0 (en) Inhibitors of phosphodiesterase-4
GB0621980D0 (en) Inhibitors of c-Met
GB0622085D0 (en) Inhibitors of HSP90
AP2009004815A0 (en) Inhibitors of phosphodiesterase type-IV
GB0621103D0 (en) Inhibitors of MEK